摘要
目的观察血管生成抑制剂参一胶囊联合化疗对乳腺癌患者术后血管内皮生长因子(VEGF)水平的影响。方法收集44例乳腺癌患者,随机分为口服参一胶囊联合化疗组和单独化疗组,收集术后3周(化疗前)、化疗1个周期和4个周期后的血清标本,采用酶联免疫吸附试验检测VEGF水平。结果两组乳腺癌患者化疗前血清VEGF水平无明显差异(P>0.05);化疗1个周期后两组VEGF水平均下降,较化疗前无明显差异(P>0.05);化疗4个周期后两组VEGF水平均显著低于化疗前(P<0.01),且联合组水平明显低于单独组(P<0.05)。结论参一胶囊联合化疗能明显降低乳腺癌患者术后的血清VEGF水平,抑制新生血管生成,降低复发转移的可能,值得临床推广应用。
Objective To investigate the effects of ginsenoside Rg3 combined with chemotherapy on serum VEGF levels in patients with postoperative breast cancers. Methods 44 patients with postoperative breast cancers were included in this study. Samples of venous blood were collected from the patients at three time points： before chemotherapy, and at the end of 1st and 4th chemotherapy cycles. Then the VEGF levels were analyzed with ELISA. Results Before chemo- therapy, there was no significant difference of VEGF level between both groups. At the end of 1 st cycle of chemotherapy, the VEGF level in two groups decreased, whereas the magnitude of reduction was not significant. And at the end of 4th cy- cle, the VEGF level in two groups showed significant decrease （ P 〈 0. 01 ） , while the experimental group＇s was higher than control group＇s （P 〈 0.05）. Conclusion Combined ginsenoside Rg3 with chemotherapy in patients with postoperative breast cancers can decrease the level of serum VEGF significantly, accordingly and effectively prevent the metastasis and relapse of mammary cancer after operation.
出处
《癌症进展》
2012年第4期374-376,共3页
Oncology Progress
